{"id":911254,"date":"2025-11-18T16:03:43","date_gmt":"2025-11-18T21:03:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/"},"modified":"2025-11-18T16:03:43","modified_gmt":"2025-11-18T21:03:43","slug":"cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/","title":{"rendered":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Nov.  18, 2025  (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to Jeffrey Hessekiel, the Company\u2019s Executive Vice President, Chief Legal and Administrative Officer, whose employment commenced on November 14, 2025, as a material inducement to his employment.<\/p>\n<p align=\"justify\">The Company also granted stock options to purchase an aggregate of 13,175 shares of common stock and 8,881 RSUs that will be settled in shares of common stock upon vesting\u00a0to an additional three employees whose employment commenced in October and November 2025 as a material inducement to their employment.<\/p>\n<p align=\"justify\">The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee\u2019s continued service with the Company. The stock options that were granted are subject to an exercise price of $66.44 per share, which is equal to the closing price of the Company\u2019s common stock on November 14, 2025 and will vest over 4 years, with 1\/4<sup>th<\/sup> of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1\/48<sup>th<\/sup> of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee\u2019s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company&#8217;s Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.<\/p>\n<p align=\"justify\">The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">\n        <strong>About Cytokinetics <\/strong>\n      <\/p>\n<p align=\"justify\">Cytokinetics\u00a0is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.\u00a0Cytokinetics\u00a0is readying for potential regulatory approvals and commercialization of\u00a0<em>aficamten,\u00a0<\/em>a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM).\u00a0<em>Aficamten<\/em>\u00a0is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM.\u00a0In addition,\u00a0Cytokinetics\u00a0is developing\u00a0<em>omecamtiv mecarbil<\/em>, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), <em>ulacamten<\/em>, a cardiac myosin inhibitor with a mechanism of action distinct from\u00a0<em>aficamten,\u00a0<\/em>for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.<\/p>\n<p align=\"justify\">For additional information about Cytokinetics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_V4AYObVsEJLkpGNkOCIkDiQnDqPtgL59IWW0CNIPaQ-5f3sCts8OnbKFr7OCy65-3pVz34DQ9jYqYTYoy_zLpZ0K9JgnIxCOkIPAJCNHcc=\" rel=\"nofollow\" target=\"_blank\">www.cytokinetics.com<\/a>\u00a0and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1yVSx_XAgnrKA4eTMeEECCNBjO8so2Budc12gTB9uaTzcPBCh3osQVoXDGghj-gvm-ev-CV1E9wuX5c26Vf1SGwyKq7TxEUcwIPByzfmuS3pr2pA76Z82begpPdqqE9REdtCCKoTEda1a1RGRuFwum8c21BHw0XhzyRWK3vcNpRMmEaosi70v6quTt5d-wea-hXabP129s4fH8jrFehCVQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mcLj1I2e06eBH4y1-iZmJm461bmPku7JJXIcyi4NPbGeq4YFgUc3Vb_mxhm2ivNrS0DTWVNmtVf_AYQ13aRJqtzGP-pyKFFB1H59piDXuC11QuMNDNeFy0rkesr1xPgHz72zZCJ_BWtkuQ5oxM7d8-4FFy4Js-bTj7Lp_vqftSDklhfye6Hmy8wCj2K1kZCIzALxd6JemQTZfDJbi-I-WxTLWxQlwr1mU7MxWyIUBbwv5DTgYx4c9_d0PZuNYl7REOFQa6fv6iYlXyEcxduoTQ==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EBw3ZvHG35sh7d1Z4p7iAOUumSIShLwR7cscElPe9vQHXkMHTgnZPy_BuKRZw-H-RQz2uauc9lGNtJ1ZNjn3D6ougoTu-PaGAJxZU7iQ2ymBFXbF5vyzQEXM9-I5eFUTPXAQEJ-iiN3kcZh--xbMBnejKGR30wgLH5wunCS4bWts--MwrRVpH-qTteYMPgw5ui6AaksFEtBTGwlL38LRnxs_7_Jrmfve0eeKFxw5B38ZW1xb_4yhjqE2RSZ16g7m\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WUrqXNNUp4wWGcsQxQl0qIK5LQGSY-FyVQ2libso8v_H0uy5rWKlNcHgcCP7OVtxbqH0Mfjhx1Xpp48Ota8ZCsaFoL3tW79n5iIgpJha9_tt_F8LtAxg0m63llU2trZrO8V8XxSzPSIi70SoTGdyYWy2Gcbxue4EZ1VzCJys828b3GR5W99o0rDbdF--xC8dBXLsY-Ovw0rp4gJyW1oAre-sYLLbRTjcT3Hse8Fr70lbtb4nQsQZEv5KE-NxgkVv99dwTl7Bhh58s8pfHu37wg==\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Disclaimer<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Aficamten, omecamtiv mecarbil, ulacamten\u00a0<\/em>and CK-089 are investigational medicines. They\u00a0have not been approved\u00a0nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the &#8220;Act&#8221;).\u00a0Cytokinetics\u00a0disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act&#8217;s\u00a0Safe Harbor\u00a0for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to\u00a0Cytokinetics&#8217;\u00a0and its partners&#8217; research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management&#8217;s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to\u00a0Cytokinetics&#8217;\u00a0business outlined in\u00a0Cytokinetics&#8217;\u00a0filings with the\u00a0Securities and Exchange Commission particularly under the caption \u201cRisk Factors\u201d in Cytokinetics\u2019 latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and\u00a0Cytokinetics&#8217;\u00a0actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that\u00a0Cytokinetics\u00a0makes in this press release speak only as of the date of this press release.\u00a0Cytokinetics\u00a0assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"justify\">CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.<\/p>\n<p align=\"justify\">Contact:<br \/>Cytokinetics <br \/>Diane Weiser<br \/>Senior Vice President, Corporate Affairs<br \/>(415) 290-7757<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWU0NWE1MmQtYzA4Zi00OTQ2LTkzZmItZjY5OTljYTc1YmJkLTEwMTY2NzYtMjAyNS0xMS0xOC1lbg==\/tiny\/Cytokinetics-Incorporated.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to Jeffrey Hessekiel, the Company\u2019s Executive Vice President, Chief Legal and Administrative Officer, whose employment commenced on November 14, 2025, as a material inducement to his employment. The Company also granted stock options to purchase an aggregate of 13,175 shares of common stock and 8,881 RSUs that will be settled in shares of common stock upon vesting\u00a0to an additional three employees whose employment commenced in October and November 2025 as a material inducement to their employment. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-911254","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to Jeffrey Hessekiel, the Company\u2019s Executive Vice President, Chief Legal and Administrative Officer, whose employment commenced on November 14, 2025, as a material inducement to his employment. The Company also granted stock options to purchase an aggregate of 13,175 shares of common stock and 8,881 RSUs that will be settled in shares of common stock upon vesting\u00a0to an additional three employees whose employment commenced in October and November 2025 as a material inducement to their employment. The &hellip; Continue reading &quot;Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T21:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\",\"datePublished\":\"2025-11-18T21:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/\"},\"wordCount\":779,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/\",\"name\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=\",\"datePublished\":\"2025-11-18T21:03:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to Jeffrey Hessekiel, the Company\u2019s Executive Vice President, Chief Legal and Administrative Officer, whose employment commenced on November 14, 2025, as a material inducement to his employment. The Company also granted stock options to purchase an aggregate of 13,175 shares of common stock and 8,881 RSUs that will be settled in shares of common stock upon vesting\u00a0to an additional three employees whose employment commenced in October and November 2025 as a material inducement to their employment. The &hellip; Continue reading \"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-18T21:03:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","datePublished":"2025-11-18T21:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/"},"wordCount":779,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/","name":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=","datePublished":"2025-11-18T21:03:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3ODA5OSM3MjcwOTgxIzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/911254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=911254"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/911254\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=911254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=911254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=911254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}